Pharmacokinetics of controlled release morphine (MST) in patients with liver carcinoma

British Journal of Anaesthesia

Volumn 94, Issue 1, 2005, Pages 95-99

  Kotb, H I M ^a   El Kady, S A ^a   Emara, S E S ^a   Fouad, E A ^b   El Kabsh, M Y ^a  

^a Assiut University Faculty of Medicine   (Egypt)

^b Assiut University   (Egypt)

Author keywords

Analgesics opioid, morphine; Drug deliver, oral; Liver, disease; Pharmacokinetics, morphine; Pharmacology, morphine

Indexed keywords

MORPHINE SULFATE; NALBUPHINE;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BLOOD OXYGEN TENSION; CANCER PAIN; CLINICAL ARTICLE; COMPARTMENT MODEL; CONSCIOUSNESS DISORDER; CONTROLLED RELEASE FORMULATION; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG ELIMINATION; HEPATITIS C; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; LIVER CARCINOMA; LIVER METASTASIS; NAUSEA; PRIORITY JOURNAL; PUBLISHING; RESPIRATION DEPRESSION; VENOUS BLOOD;

EID: 11344287563     PISSN: 00070912     EISSN: None     Source Type: Journal    
DOI: 10.1093/bja/aei007     Document Type: Article

References (15)

1. Kaltenback BL, Becker AJ. Use of opioids in adults with chronic cancer pain. Health Care 2002; 1: 1-7
2. Hasselström J, Säwe J. Morphine pharmacokinetics and metabolism in humans. Enterohepatic cycling and relative contribution of metabolites to active opioid concentrations. Clin Pharmacokinet 1993; 24: 344-54
3. Muir C, Waterhouse J, Mack T, et al. Cancer Incidence in Five Continents, World Health Organization, Vol V. IARC Scientific Publications. Lyon: IARC, 1987; No. 88
4. Rustgi VK, Epidemiology of hepatocellular carcinoma. Gastroenterol Clin North Am 1987; 16: 545-51
5. Kubicka S, Rudolph KL, Hanke M, et al. Hepatocellular carcinoma in Germany: a retrospective epidemiological study from a low-endemic area. Liver 2000; 20: 312-8
6. Kotb HI, El-Kabsh MY, Emara SE, Fouad EA. Pharmacokinetics of controlled release morphine (MST) in patients with liver cirrhosis. Br J Anaesth 1997; 79: 804-6
7. Yamaoka K, Nakagawa T. A non linear least squares program based on differential equations, MULTI (Ruge) for microcomputer. J Pharmacobiol Dynam 1983; 6: 395-606
8. Morgan DJ, McLean AJ. Clinical pharmacokinetic and pharmacodynamic considerations in patients with liver disease: an update. Clin Pharmacokinet 1995; 29: 370-91
9. Kawasak S, Imamura H, Bandai Y, et al. Direct evidence for the intact hepatocyte theory in patients with liver cirrhosis. Gastroenterology 1992; 102: 1351-5
10. Robertz-Vaupel GM, Lindecken KD, Edeki S, et al. Disposition of antipyrine in patients with extensive metastatic liver disease. Eur J Clin Pharmacol 1992; 42: 450-9
11. Neal APS, Datta DV, Wath W, Mathur VS. Enhanced bioavailability and decreased clearance of analgesics in patients with cirrhosis. Gastroenterology 1979; 77: 96-102
12. Sherlock S, Dooley J. Malignant liver tumours (31). In: Sherlock S and Dooley J, eds. Diseases of the Liver and Biliary System Oxford: Blackwell Scientific Publications, 2002; 537-61
13. Debinski HS, Lee CS, Danks JA, et al. Localization of 5′-diphosphate-glucuronyl-transferase in human liver injury. Gastroenterology 1995; 108: 1464-9
14. Reichen J. hepatic spaces and transport in the perfused liver. In: Petzinger E, Kinne RK-J, Sies H, eds. Hepatic Transport in Organic Substances. Berlin: Springer-Verlag, 1989; 45-56.
15. Xie R, Hammar-lund-Udenaes M, de Boer AG, et al. The role of P-glycoprotein in blood brain barrier transport of morphine: transcortical microdialysis studies in mdrla (-/-) and mdrla (+/+) mice. Br J Pharmacol 1999; 128: 563-8